Review of bioinformatics and theoretical studies of acetylcholinesterase inhibitors

Current Bioinformatics

Volumn 8, Issue 4, 2013, Pages 496-510

  Prado Prado, Francisco J ^a   Escobar, Manuel ^b   García Mera, Xerardo ^b  

^a UNIVERSIDAD DE QUINTANA ROO   (Mexico)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; COMFA; CoMSIA; Molecular docking; QSAR; Topological indices

Indexed keywords

BIOINFORMATICS; COMPUTATIONAL CHEMISTRY; DISCRIMINANT ANALYSIS; DRUG INTERACTIONS; MOLECULAR GRAPHICS;

ACETYLCHOLINESTERASE INHIBITORS; ALZHEIMER; ALZHEIMERS DISEASE; COMFA; COMSIA; MOLECULAR DOCKING; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP; STRUCTURAL REQUIREMENTS; THEORETICAL STUDY; TOPOLOGICAL INDEX;

NEURODEGENERATIVE DISEASES;

CARBAMIC ACID DERIVATIVE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GANSTIGMINE; INDANONE DERIVATIVE; MEMANTINE; NEUROTRANSMITTER; PHYSOSTIGMINE DERIVATIVE; RIVASTIGMINE; TACRINE DERIVATIVE; TERPENE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; BIOINFORMATICS; CHOLINERGIC TRANSMISSION; DISEASE COURSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TREATMENT FAILURE; HUMAN; HYDROLYSIS; IMAGING SYSTEM; MACHINE LEARNING; MENTAL FUNCTION; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TETRANYCHUS URTICAE; THEORETICAL STUDY; UNSPECIFIED SIDE EFFECT;

EID: 84882749776     PISSN: 15748936     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574893611308040012     Document Type: Review

References (102)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362(4): 329-44.
2. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349(6311): 704-6.
3. Levy-Lahad E, Wasco W, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269(5226): 973-7.
4. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375(6534): 754-60.
5. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997; 3(1): 67-72.
6. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998; 4(1): 97-100.
7. Cole SL, Vassar R. The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener 2007; 2: 22.
8. Cole SL, Vassar R. The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease. Curr Genomics 2007; 8(8): 509-30.
9. Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991; 253(5022): 872-9.
10. Botti SA, Felder CE, Lifson S, Sussman JL, Silman I. A modular treatment of molecular traffic through the active site of cholinesterase. Biophys J 1999; 77(5): 2430-50.
11. Chou KC. Structural bioinformatics and its impact to biomedical science. Curr Med Chem 2004; 11(16): 2105-34.
12. Chou KC, Wei DQ, Du QS, Sirois S, Zhong WZ. Progress in computational approach to drug development against SARS. Curr Med Chem 2006; 13(27): 3263-70.
13. Todeschini R, Consonni V. Handbook of Molecular Descriptors. Wiley-VCH: 2002.
14. Estrada E, Uriarte E. Recent advances on the role of topological indices in drug discovery research. Curr Med Chem 2001; 8: 1573-88.
15. González-Díaz H, González-Díaz Y, Santana L, Ubeira FM, Uriarte E. Proteomics, networks and connectivity indices. Proteomics 2008; 8: 750-78.
16. Nunez MB, Maguna FP, Okulik NB, Castro EA. QSAR modeling of the MAO inhibitory activity of xanthones derivatives. Bioorg Med Chem Lett 2004; 14(22): 5611-7.
17. Terada M, Inaba M, Yano Y, et al. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone 1998; 22(1): 17-23.
18. Santana L, Uriarte E, González-Díaz H, Zagotto G, Soto-Otero R, Mendez-Alvarez E. A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J Med Chem 2006; 49(3): 1149-56.
19. Marrero-Ponce Y. Linear indices of the molecular pseudograph's atom adjacency matrix: definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. J Chem Inf Comput Sci 2004; 44(6): 2010-26.
20. Vilar S, Santana L, Uriarte E. Probabilistic neural network model for the in silico evaluation of anti-HIV activity and mechanism of action. J Med Chem 2006; 49(3): 1118-24.
21. Marrero-Ponce Y, Khan MT, Casanola Martin GM, et al. Prediction of Tyrosinase Inhibition Activity Using Atom-Based Bilinear Indices. ChemMedChem 2007; 2(4): 449-78.
22. Casanola-Martin GM, Marrero-Ponce Y, Khan MT, et al. TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors: evaluation of different classification model combinations using bond-based linear indices. Bioorg Med Chem 2007; 15(3): 1483-503.
23. Casanola-Martin GM, Marrero-Ponce Y, Khan MT, et al. Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays. Eur J Med Chem 2007; 42(11-12): 1370-81.
24. Chen J, Shen B. Computational Analysis of Amino Acid Mutation: a Proteome Wide Perspective. Curr Proteomics 2009; 6(4): 228-34.
25. Chou KC. Pseudo amino acid composition and its applications in bioinformatics, proteomics and system biology. Curr Proteomics 2009; 6(4): 262-74.
26. Berca MN, Duardo-Sanchez A, González-Díaz H, Pazos A, Munteanu CR. In: González-Díaz H, Prado-Prado FJ, García-Mera X, Eds. Complex Network Entropy: From Molecules to Biology, Parasitology, Technology, Social, Legal, and Neurosciences. Kerala, India, Transworld Research Network 2011;127-42.
27. Vilar S, Gonzalez-Diaz H, Santana L, Uriarte E. A network-QSAR model for prediction of genetic-component biomarkers in human colorectal cancer. J Theor Biol 2009; 261(3): 449-58.
28. Concu R, Dea-Ayuela MA, Perez-Montoto LG, et al. 3D entropy and moments prediction of enzyme classes and experimentaltheoretic study of peptide fingerprints in Leishmania parasites. Biochim Biophys Acta 2009; 1794(12): 1784-94.
29. Fjodorova N, Novich M, Vrachko M, et al. Regulatory assessment of chemicals within OECD member countries, EU and in Russia. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2008; 26(1): 40-88.
30. Duardo-Sanchez A. In: González-Díaz H, Prado-Prado FJ, García-Mera X, Eds. Complex Network Entropy: From Molecules to Biology, Parasitology, Technology, Social, Legal, and Neurosciences. Kerala, India, Transworld Research Network 2011;107-14.
31. Gonzalez-Diaz H. Quantitative studies on Structure-Activity and Structure-Property Relationships (QSAR/QSPR). Curr Top Med Chem 2008; 8(18): 1554.
32. Ivanciuc O. Weka machine learning for predicting the phospholipidosis inducing potential. Curr Top Med Chem 2008; 8(18): 1691-709.
33. Gonzalez-Diaz H, Prado-Prado F, Ubeira FM. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr Top Med Chem 2008; 8(18): 1676-90.
34. Duardo-Sanchez A, Patlewicz G, Lopez-Diaz A. Current topics on software use in medicinal chemistry: intellectual property, taxes, and regulatory issues. Curr Top Med Chem 2008; 8(18): 1666-75.
35. Wang JF, Wei DQ, Chou KC. Drug candidates from traditional chinese medicines. Curr Top Med Chem 2008; 8(18): 1656-65.
36. Pillay D, Cane PA, Ratcliffe D, Atkins M, Cooper D. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR coordinating committee. AIDS 2000; 14(9): 1111-6.
37. Gonzalez MP, Teran C, Saiz-Urra L, Teijeira M. Variable selection methods in QSAR: an overview. Curr Top Med Chem 2008; 8(18): 1606-27.
38. Caballero J, Fernandez M. Artificial neural networks from MATLAB in medicinal chemistry. Bayesian-regularized genetic neural networks (BRGNN): application to the prediction of the antagonistic activity against human platelet thrombin receptor (PAR-1). Curr Top Med Chem 2008; 8(18): 1580-605.
39. Wang JF, Wei DQ, Chou KC. Pharmacogenomics and personalized use of drugs. Curr Top Med Chem 2008; 8(18): 1573-9.
40. Vilar S, Cozza G, Moro S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem 2008; 8(18): 1555-72.
41. Prado-Prado FJ, Garcia-Mera X, Gonzalez-Diaz H. Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorg Med Chem 2010; 18(6): 2225-31.
42. Lin YY, Qi Y, Lu JY, et al. A comprehensive synthetic genetic interaction network governing yeast histone acetylation and deacetylation. Genes Dev 2008; 22(15): 2062-74.
43. Zotenko E, Mestre J, O'Leary DP, Przytycka TM. Why do hubs in the yeast protein interaction network tend to be essential: reexamining the connection between the network topology and essentiality. PLoS Comput Biol 2008; 4(8): e1000140.
44. Hase T, Niimura Y, Kaminuma T, Tanaka H. Non-uniform survival rate of heterodimerization links in the evolution of the yeast protein-protein interaction network. PLoS ONE 2008; 3(2): e1667.
45. Kafri R, Dahan O, Levy J, Pilpel Y. Preferential protection of protein interaction network hubs in yeast: evolved functionality of genetic redundancy. Proc Natl Acad Sci U S A 2008; 105(4): 1243-8.
46. Jin G, Zhang S, Zhang XS, Chen L. Hubs with network motifs organize modularity dynamically in the protein-protein interaction network of yeast. PLoS ONE 2007; 2(11): e1207.
47. Fernandez A. Molecular basis for evolving modularity in the yeast protein interaction network. PLoS Comput Biol 2007; 3(11): e226.
48. Batada NN, Reguly T, Breitkreutz A, et al. Stratus not altocumulus: a new view of the yeast protein interaction network. PLoS Biol 2006; 4(10): e317.
49. Li L, Huang Y, Xia X, Sun Z. Preferential duplication in the sparse part of yeast protein interaction network. Mol Biol Evol 2006; 23(12): 2467-73.
50. Chou KC. Graphic rule for drug metabolism systems. Curr Drug Metab 11(4): 369-78.
51. Nassif H, Al-Ali H, Khuri S, Keirouz W. Prediction of proteinglucose binding sites using support vector machines. Proteins 2009; 77(1): 121-32.
52. Del Rio A, Baldi BF, Rastelli G. Activity prediction and structural insights of extracellular signal-regulated kinase 2 inhibitors with molecular dynamics simulations. Chemical biology & drug design 2009; 74(6): 630-5.
53. Garcia I, Fall Y, Gomez G. QSAR, docking, and CoMFA studies of GSK3 inhibitors. Curr Pharm Des 2010; 16(24): 2666-75.
54. Le T, Tseng TT, Saier MH, Jr. Flexible programs for the prediction of average amphipathicity of multiply aligned homologous proteins: application to integral membrane transport proteins. Mol Membr Biol 1999; 16(2): 173-9.
55. Gonzalez-Diaz H, Romaris F, Duardo-Sanchez A, et al. redicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, aplications, and legal issues. Curr Pharm Des 2010; 16(24): 2737-64.
56. Marrero-Ponce Y, Casanola-Martin GM, Khan MT, Torrens F, Rescigno A, Abad C. Ligand-Based Computer-Aided Discovery of Tyrosinase Inhibitors. Applications of the TOMOCOMD-CARDD Method to the Elucidation of New Compounds. Curr Pharm Des 2010; 16(24): 2601-24.
57. Munteanu CR, Fernandez-Blanco E, Seoane JA, et al. Drug discovery and design for complex diseases through QSAR computational methods. Curr Pharm Des 2010; 16(24): 2640-55.
58. Roy K, Ghosh G. Exploring QSARs with Extended Topochemical Atom (ETA) Indices for Modeling Chemical and Drug Toxicity. Curr Pharm Des 2010; 16(24): 2625-39.
59. Speck-Planche A, Scotti MT, de Paulo-Emerenciano V. Current pharmaceutical design of antituberculosis drugs: future perspectives. Curr Pharm Des 2010; 16(24): 2656-65.
60. Veluraja K, Seethalakshmi AN. Dynamics of sialyl Lewis(a) in aqueous solution and prediction of the structure of the sialyl Lewis(a)-SelectinE complex. J Theor Biol 2008; 252(1): 15-23.
61. Bhattacharjee B, Jayadeepa RM, Banerjee S, et al. Review of Complex Network and Gene Ontology in pharmacology approaches: Mapping natural compounds on potential drug target Colon Cancer network. Current Bioinformatics 2011; 6(1): 44-52.
62. Chiş O, Dumitru O, Concu R, Shen B. Reviewing Yeast Network and report of new Stochastic-Credibility cell cycle models. Current Bioinformatics 2011; 6(1): 35-43.
63. Dave K, Banerjee A. Bioinformatics analysis of functional relations between CNPs regions. Current Bioinformatics 2011; 6(1): 122-8.
64. Duardo-Sanchez A, Patlewicz G, González-Díaz H. A Review of Network Topological Indices from Chem-Bioinformatics to Legal Sciences and back. Current Bioinformatics 2011; 6(11): 53-70.
65. García I, Fall Y, Gómez G. Trends in Bioinformatics and Chemoinformatics of Vitamin D analogues and their protein targets. Current Bioinformatics 2011; 6(1): 16-24.
66. Ivanciuc T, Ivanciuc O, Klein DJ. Network-QSAR with Reaction Poset Quantitative Superstructure-Activity Relationships (QSSAR) for PCB Chromatographic Properties. Current Bioinformatics 2011; 6(1): 25-34.
67. Prado-Prado F, Escobar-Cubiella M, García-Mera X. Review of Bioinformatics and QSAR studies of -secretase inhibitors. Current Bioinformatics 2011; 6(1): 3-15.
68. Riera-Fernández P, Munteanu CR, Pedreira-Souto N, Duardo-Sanchez A, González-Díaz H. Definition of Markov-Harary Invariants and Review of Classic Topological Indices and Databases of Biology, Parasitology, Technology, and Social-Legal Networks. Current Bioinformatics 2011; 6(1): 94-121.
69. Speck-Planche A, Cordeiro MNDS. Application of Bioinformatics for the search of novel anti-viral therapies: Rational design of antiherpes agents. Current Bioinformatics 2011; 6(1): 81-93.
70. Wan SB, Hu LL, Niu S, et al. Identification of multiple subcellular locations for proteins in budding yeast. Current Bioinformatics 2011; 6(1): 71-80.
71. Estrada E. On the topological sub-structural molecular design (TOSS-MODE) in QSPR/QSAR and drug design research. SAR QSAR Environ Res 2000; 11(1): 55-73.
72. Brady CP, Dowd AJ, Tort J, et al. The cathepsin L-like proteinases of liver fluke and blood fluke parasites of the trematode genera Fasciola and Schistosoma. Biochem Soc Trans 1999; 27(4): 740-5.
73. Badawy ME, El-Arami SA, Abdelgaleil SA. Acaricidal and quantitative structure activity relationship of monoterpenes against the two-spotted spider mite, Tetranychus urticae. Exp Appl Acarol 2010; 52(3): 261-74.
74. Vitorovic-Todorovic MD, Juranic IO, Mandic LM, Drakulic BJ. 4- Aryl-4-oxo-N-phenyl-2-aminylbutyramides as acetyl-and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure-activity relationship based on molecular interaction fields. Bioorganic & medicinal chemistry 2010; 18(3): 1181-93.
75. Lv W, Xue Y. Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods. Eur J Med Chem 2010; 45(3): 1167-72.
76. Ul-Haq Z, Mahmood U, Jehangir B. Ligand-based 3D-QSAR studies of physostigmine analogues as acetylcholinesterase inhibitors. Chemical biology & drug design 2009; 74(6): 571-81.
77. Chaudhaery SS, Roy KK, Saxena AK. Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors. Journal of chemical information and modeling 2009; 49(6): 1590-601.
78. Armutlu P, Ozdemir ME, Uney-Yuksektepe F, Kavakli IH, Turkay M. Classification of drug molecules considering their IC50 values using mixed-integer linear programming based hyper-boxes method. BMC Bioinformatics 2008; 9: 411.
79. Shen LL, Liu GX, Tang Y. Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors. Acta pharmacologica Sinica 2007; 28(12): 2053-63.
80. Ahn JH, Shin MS, Jung SH, et al. Synthesis and structure-activity relationship of novel indene N-oxide derivatives as potent peroxisome proliferator activated receptor gamma (PPARgamma) agonists. Bioorg Med Chem Lett 2007; 17(18): 5239-44.
81. Akula N, Lecanu L, Greeson J, Papadopoulos V. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA. Bioorganic & medicinal chemistry letters 2006; 16(24): 6277-80.
82. Fontaine F, Pastor M, Zamora I, Sanz F. Anchor-GRIND: filling the gap between standard 3D QSAR and the GRid-INdependent descriptors. J Med Chem 2005; 48(7): 2687-94.
83. Guo J, Hurley MM, Wright JB, Lushington GH. A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition. J Med Chem 2004; 47(22): 5492-500.
84. Martin-Santamaria S, Munoz-Muriedas J, Luque FJ, Gago F. Modulation of binding strength in several classes of active site inhibitors of acetylcholinesterase studied by comparative binding energy analysis. J Med Chem 2004; 47(18): 4471-82.
85. Sippl W, Contreras JM, Parrot I, Rival YM, Wermuth CG. Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors. J Comput Aided Mol Des 2001; 15(5): 395-410.
86. Salmon SA, Watts JL. Minimum inhibitory concentration determinations for various antimicrobial agents against 1570 bacterial isolates from turkey poults. Avian Dis 2000; 44(1): 85-98.
87. Chou KC. Review: Structural bioinformatics and its impact to biomedical science. Curr Med Chem 2004; 11: 2105-34.
88. Chou KC, Wei DQ, Du QS, Sirois S, Zhong WZ. Review: Progress in computational approach to drug development against SARS. Curr Med Chem 2006; 13: 3263-70.
89. Prado-Prado FJ, Gonzalez-Diaz H, de la Vega OM, Ubeira FM, Chou KC. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorg Med Chem 2008; 16(11): 5871-80.
90. Prado-Prado FJ, de la Vega OM, Uriarte E, Ubeira FM, Chou KC, Gonzalez-Diaz H. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorg Med Chem 2009; 17: 569-75.
91. Kubinyi H. Quantitative structure-activity relationships (QSAR) and molecular modelling in cancer research. J Cancer Res Clin Oncol 1990; 116(6): 529-37.
92. Prado-Prado FJ, Borges F, Perez-Montoto LG, Gonzalez-Diaz H. Multi-target spectral moment: QSAR for antifungal drugs vs different fungi species. Eur J Med Chem 2009.
93. Overington J., Ch EMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBLEBI). Interview by Wendy A. Warr. J Comput Aided Mol Des 2009; 23(4): 195-8.
94. Estrada E, Patlewicz G, Chamberlain M, Basketter D, Larbey S. Computer-aided knowledge generation for understanding skin sensitization mechanisms: the TOPS-MODE approach. Chem Res Toxicol 2003; 16(10): 1226-35.
95. Estrada E, Uriarte E, Gutierrez Y, Gonzalez H. Quantitative structure-toxicity relationships using TOPS-MODE. 3. Structural factors influencing the permeability of commercial solvents through living human skin. SAR QSAR Environ Res 2003; 14(2): 145-63.
96. Estrada E, Gonzalez H. What are the limits of applicability for graph theoretic descriptors in QSPR/QSAR? Modeling dipole moments of aromatic compounds with TOPS-MODE descriptors. J Chem Inf Comput Sci 2003; 43(1): 75-84.
97. Estrada E, Vilar S, Uriarte E, Gutierrez Y. In silico studies toward the discovery of new anti-HIV nucleoside compounds with the use of TOPS-MODE and 2D/3D connectivity indices. 1. Pyrimidyl derivatives. J Chem Inf Comput Sci 2002; 42(5): 1194-203.
98. Estrada E. Quantum-chemical foundations of the topological substructural molecular design. J Phys Chem A 2008; 112(23): 5208-17.
99. Yoshii F, Hirono S. Construction of a quantitative threedimensional model for odor quality using comparative molecular field analysis (CoMFA). Chem Senses 1996; 21(2): 201-10.
100. Gonzalez-Diaz H, Saiz-Urra L, Molina R, Santana L, Uriarte E. A model for the recognition of protein kinases based on the entropy of 3D van der Waals interactions. Journal of proteome research 2007; 6(2): 904-8.
101. Alvarez-Ginarte YM, Marrero-Ponce Y, Ruiz-Garcia JA, et al. Applying pattern recognition methods plus quantum and physicochemical molecular descriptors to analyze the anabolic activity of structurally diverse steroids. J Comput Chem 2007.
102. Morales AH, Rodríguez-Borges JE, García-Mera X, Fernández F, Dias-Sueiro-Cordeiro MN. Probing the Anticancer Activity of Nucleoside Analogues: A QSAR Model Approach Using an Internally Consistent Training Set. J Med Chem 2007; 50: 1537-45.